ABSTRACT
Introduction Sickle cell disease (SCD) is associated with the development of hypogonadism, but there is still controversy regarding its etiology and clinical implications.
Objective To evaluate the prevalence of hypogonadism in a population of men with SCD and characterize its etiology.
Methods We performed a cross-sectional study of 34 men with SCD aged > 18 years. Sociodemographic and clinical data, including anthropometric measurements (weight, height, and BMI), were obtained. Early morning blood samples were collected and total testosterone (TT), free testosterone (FT), luteinizing hormone (LH), follicle-stimulating hormone (FSH), a complete blood count, and hemoglobin electrophoresis were measured.
Results Median age was 33 [26-41] years, and SS genotype was the most frequent (73.5%). The prevalence of eugonadism, compensated, and secondary hypogonadism was 67.5%, 26.4%, and 5.88%, respectively. No men with primary hypogonadism were identified in our sample. Those with compensated hypogonadism had also higher FSH levels than individuals with eugonadism; p < 0.001).
Conclusion In our study population of men with SCD a high prevalence of compensated hypogonadism was identified, which is a controversial and distinct clinical entity that warrants monitoring and further research.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
No external fundings
Author Declarations
All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Data are attached as supplement in submission to Plos One
